Quick Answer
Immunocore Holdings plc reported Research And Development Expense of $274.87 million for the year ending 2025.
- Immunocore Holdings plc showed an increase of +23.7% in Research And Development Expense from 2024 to 2025.
- This data is from Immunocore Holdings plc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $36.57 million | Q2 2023: $38.16 million | Q3 2023: $43.25 million | Q1 2024: $57.46 million | Q2 2024: $51.07 million | Q3 2024: $52.77 million | Q1 2025: $56.47 million | Q2 2025: $69.01 million | Q3 2025: $70.57 million.
- Over the full 8 years of available data (2018 to 2025), Immunocore Holdings plc's Research And Development Expense has grown by 228.9%.
- Historical annual values: Fiscal year 2025: $274.87 million | Fiscal year 2024: $222.15 million | Fiscal year 2023: $163.55 million | Fiscal year 2022: $101.92 million | Fiscal year 2021: $100.25 million | Fiscal year 2020: $74.81 million | Fiscal year 2019: $99.99 million | Fiscal year 2018: $83.58 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: